Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (11-20 of 219) with videos related to

Pageof 22
Sort By:
BMC Dermatology|October 28, 2006
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrenceKim A Papp, Darryl Toth, Les Rosoph
The Journal of Rheumatology|April 5, 2011
Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsEdward C Keystone, Kim A Papp, Wendy Wobeser
Clinical Rheumatology|January 17, 2012
Managing cardiovascular risk in patients with chronic inflammatory diseasesBoulos Haraoui, Peter P Liu, Kim A Papp
Journal of the American Academy of Dermatology|November 22, 2011
Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adultsKim A Papp, Alexine Papp, Betty Dahmer, et al.
Lancet (London, England)|April 25, 2021
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b studyKim A Papp, Mark A Weinberg, Alun Morris, et al.
Journal of Cutaneous Medicine and Surgery|April 19, 2021
Response to Reader Comment on "Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis"Véronique Gaudet, Martin Barbeau, Shoghag Khoudigian-Sinani, et al.
Journal of Cutaneous Medicine and Surgery|April 25, 2006
A favourable benefit/risk ratio with efalizumab: a review of the clinical evidenceYves Poulin, Kim A Papp, Wayne Carey, et al.
Journal of the American Academy of Dermatology|February 24, 2018
Dupilumab: A review of its use in the treatment of atopic dermatitisMelinda J Gooderham, H Chih-Ho Hong, Panteha Eshtiaghi, et al.
American Journal of Clinical Dermatology|November 9, 2015
Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical TrialsKim A Papp, April W Armstrong, Kristian Reich, et al.
Lancet (London, England)|February 5, 2016
Ixekizumab for psoriasis--Authors' replyChristopher E M Griffiths, Kim A Papp, Susan G Ball, et al.
Pageof 22

Showing results (11-20 of 219) with videos related to

Sort By:
Pageof 22
BMC Dermatology|October 28, 2006
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrenceKim A Papp, Darryl Toth, Les Rosoph
The Journal of Rheumatology|April 5, 2011
Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsEdward C Keystone, Kim A Papp, Wendy Wobeser
Clinical Rheumatology|January 17, 2012
Managing cardiovascular risk in patients with chronic inflammatory diseasesBoulos Haraoui, Peter P Liu, Kim A Papp
Journal of the American Academy of Dermatology|November 22, 2011
Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adultsKim A Papp, Alexine Papp, Betty Dahmer, et al.
Lancet (London, England)|April 25, 2021
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b studyKim A Papp, Mark A Weinberg, Alun Morris, et al.
Journal of Cutaneous Medicine and Surgery|April 19, 2021
Response to Reader Comment on "Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis"Véronique Gaudet, Martin Barbeau, Shoghag Khoudigian-Sinani, et al.
Journal of Cutaneous Medicine and Surgery|April 25, 2006
A favourable benefit/risk ratio with efalizumab: a review of the clinical evidenceYves Poulin, Kim A Papp, Wayne Carey, et al.
Journal of the American Academy of Dermatology|February 24, 2018
Dupilumab: A review of its use in the treatment of atopic dermatitisMelinda J Gooderham, H Chih-Ho Hong, Panteha Eshtiaghi, et al.
American Journal of Clinical Dermatology|November 9, 2015
Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical TrialsKim A Papp, April W Armstrong, Kristian Reich, et al.
Lancet (London, England)|February 5, 2016
Ixekizumab for psoriasis--Authors' replyChristopher E M Griffiths, Kim A Papp, Susan G Ball, et al.
Pageof 22